Has Wallace Peterson, MD received payments from drug or device companies?

Yes. Drug and device makers reported $5,193 in general payments to Wallace Peterson, MD across 315 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Wallace Peterson, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Wallace Peterson, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Wallace Peterson, MD

Hematology & Oncology · Lincoln, NENPI 1760472039

Payments from drug & device makers

$5,193in general payments, 2019–2025

Across 315 payments — averaging $16.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

E.r. Squibb & Sons, L.L.C.$473
Pfizer$408
Bristol Myers Squibb$372
Novartis$310
Pharmacyclics LLC, An Abbvie Company$299
Incyte Corporation$298
plus $3K from 49 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
E.r. Squibb & Sons, L.L.C.	29	$473
Pfizer	34	$408
Bristol Myers Squibb	28	$372
Novartis	19	$310
Pharmacyclics LLC, An Abbvie Company	19	$299
Incyte Corporation	9	$298
Merck	14	$258
AbbVie	14	$254
Johnson & Johnson	9	$226
Seagen Inc.	10	$175
Array Biopharma Inc	9	$155
AstraZeneca(2 entities)	10	$155
Eisai Inc.	7	$118
GSK	7	$109
Lilly USA, LLC	1	$109
Sanofi	6	$105
AVEO Pharmaceuticals, Inc.	4	$95
Daiichi Sankyo Inc.	6	$85
Amgen	6	$79
Genentech USA, Inc.	5	$78
Astellas Pharma US Inc	5	$77
CTI Biopharma Corp.	4	$62
Takeda Pharmaceuticals U.S.A., Inc.	4	$58
EMD Serono, Inc.	3	$55
Gilead	4	$55
Agios Pharmaceuticals, Inc.	3	$47
Servier Pharmaceuticals LLC	2	$43
Immunogen, Inc.	2	$41
Blueprint Medicines Corporation	2	$40
Tersera Therapeutics LLC	2	$36
Jazz Pharmaceuticals Inc.	2	$34
Blue Earth Diagnostics	2	$34
Sobi, Inc	2	$33
Sunovion Pharmaceuticals Inc.	3	$30
Taiho Oncology, Inc.	2	$30
Novocure Inc.	4	$28
Mylan Institutional Inc.	2	$28
Bayer	2	$25
Adaptive Biotechnologies Corporation	2	$25
Dova Pharmaceuticals	2	$25
G1 Therapeutics, Inc.	1	$24
Azurity Pharmaceuticals, Inc.	1	$18
Sumitomo Pharma America, Inc.	1	$17
Karyopharm Therapeutics Inc.	1	$15
Regeneron Healthcare Solutions, Inc.	1	$15
Deciphera Pharmaceuticals Inc.	1	$15
Sun Pharmaceutical Industries Inc.	1	$14
Myriad Genetic Laboratories, Inc.	1	$14
Tesaro, Inc.	1	$14
Epizyme, Inc.	1	$14
Exelixis Inc.	1	$13
Octapharma USA, Inc.	1	$13
Ipsen Biopharmaceuticals, Inc	1	$13
Apellis Pharmaceuticals, Inc.	1	$13
Myovant Sciences Inc.	1	$12

How this compares

$5,193 in reported general payments places this provider in the 35th percentile of 73 hematology & oncology providers in Nebraska.

See all hematology & oncology providers in Nebraska →

Medicare billing

Part B allowed, 2024

$3,350,457

Medicare patients

897

Services billed

151,488

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Lincoln

Kailash MosalpuriaLincoln$4.2M
Madhu MidathadaLincoln$1.1M
Mark HutchinsLincoln$1.1M
Eric AveryLincoln$1.1M
Steven DunderLincoln$612K
Stacey KnoxLincoln$573K
Alan BergLincoln$396K
Joni TilfordLincoln$181K
Nathan GreenLincoln$136K
Scott McHamLincoln$33K

See the full list for Nebraska →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →